Introduction
Patients with rheumatoid arthritis (RA) typically experience substantial loss of lean mass (LM), primarily muscle mass (MM), and increased fat mass (FM), especially trunk FM, in a process known as "rheumatoid cachexia" (RC) (1) . Thought to be driven by inlammation, speciically pro-inlammatory cytokines such as tumor necrosis factor-α, RC is a major contributor to decreased strength and impaired physical function and exacerbated co-morbidity risk, which characterize RA (1) (2) (3) . Unfortunately, despite usually achieving successful control of inlammation and disease activity, current treatment of RA does not reverse these adverse changes in body composition (3).
When RA is "active" (i.e., before starting drug treatment or during a disease lare in established RA), one-of administration of high-dose corticosteroid (CS), often by intramuscular (IM) injection, is recommended in clinical guidelines (e.g., American College of Rheumatology (ACR), European League against Rheumatism (EULAR), British Society for Rheumatology (BSR), and NICE Clinical Guidelines 79, 2009) owing to its eicacy in rapidly reducing inlammation and pain (4) (5) (6) (7) (8) . While long-term high-dose CS treatment is known to have detrimental efects on body composition including loss of LM and an increase in FM, the efects on body composition of single high-dose CS treatment, including IM CS injection, are unclear (9) .
Our interest in the body composition efects of acute CS treatment was stimulated by the observation of a substantial loss of dual-energy X-ray absorptiometry (DXA)-assessed MM (-2.0 kg in appendicular lean 
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To our knowledge, this pilot study is the irst to investigate the efects on body composition of a single high-dose IM CS injection. We hypothesized that this routine, recommended treatment for high RA disease activity exacerbates muscle loss and thus could contribute to the impaired physical function seen in patients with RA.
Methods Participants
Patients with established RA presenting with a disease flare and treated with an IM injection of CS were recruited from the rheumatology outpatient clinics of the Peter Maddison Rheumatology Centre, Gwynedd Hospital. For inclusion, participants had to: (a) fulfill the ACR/EULAR 2010 revised classification criteria for the diagnosis of RA, (b) have uncontrolled RA disease activity for which IM CS injection was deemed to be the appropriate treatment, (c) be aged ≥18 years, (d) not be cognitively impaired, (e) be free of other cachectic diseases or conditions, (f ) not be pregnant, and (g) not have any contraindication to high-dose IM CS injection (e.g., uncontrolled diabetes mellitus, active infection, and previous hypersensitivity to CS injections).
This pragmatic, uncontrolled, pre-post-intervention pilot study was approved by the North Wales Research Ethics Committee -West (15/ WA/0013).
Clinical assessments and treatment
Active disease (i.e., lare) was determined by the attending consultant rheumatologist following clinical assessment. If considered appropriate by the same rheumatologist, and patient consent was obtained, a standard CS injection, 120 mg of Depomedrone (methylprednisolone acetate aqueous solution), was administered into the gluteal muscle.
Patient's disease activity (Disease Activity Score in 28 joints, DAS28-CRP) and systemic inlammation (C-reactive protein, CRP) were determined at baseline (immediately prior to injection) and during routine rheumatology follow-up clinics at approximately 4 weeks (27-32 days) and 6-9 months post-injection.
Body composition measures
DXA scans were performed within 1 hour of the patient receiving the injection (baseline) and repeated at ~4 weeks and 6-9 months post-injection. Total and regional lean and fat masses, along with bone mineral content (BMC) and density (BMD), were estimated using a whole body fan beam DXA scanner (Hologic, QDR Discovery 45615, software V12.4). ALM (the summed LM of the arms and legs) served as a surrogate measure of total body MM (3). The in-house coeicient of variation of 1.4% of our scanner complies with the manufacturer's guidelines (3).
Statistical analysis
The primary outcome measure was DXA-assessed ALM, with secondary outcome measures of: disease activity (DAS28-CRP) and systemic inlammation (CRP) and other body composition variables: total LM, % ALM relative to body mass (BM) (ALM/BM %), total FM, trunk FM, % FM relative to BM (% body fat), % trunk FM relative to total FM (trunk FM %), BMC, and BMD.
Data analyses were performed by one-way ANOVAs (three time-points), with efect size (small=0.20-0.49, medium=0.50-0.79, and large ≥0.80) calculated for each variable. Data analyses were performed using the Statistical Package for the Social Sciences 22 (IBM Corp.; Armonk, NY, USA). Data are generally presented as mean (±SD), with between-time diferences presented as mean (±95% conidence intervals, 95% CI), and, where appropriate, range is also given. Signiicance was set at p<0.05.
Results
Nine patients with RA who received an IM CS injection to treat a lare of disease were deemed eligible for the study and consented to participate. Assessments at baseline, 4 weeks, and 6-9 months post-injection were performed on eight patients, as one participant withdrew from the study after baseline measurements owing to suspected meningitis. The mean interval between CS injection and baseline DXA scan was 0.7 h (~42 min; range: 18-60 min). Table 1 shows the baseline demographic data for the eight patients who completed the study. All patients had established disease (mean duration ~11 years, range: 2.0-46.8 years) and were on standard disease-modifying anti-rheumatic drug therapy. None of these patients, either at the time of the CS injection or over the ensuing 6-9 months, were treated with either biologics or oral steroids. Patients reported no substantial changes to lifestyle (e.g., diet or exercise) or adverse health events, over the trial period.
Signiicant reductions in DAS28-CRP (p=0.049, 95% CI [-0.82, -2.30]) and CRP (p=0.023, 95% CI [-0.78, -28.95]) from baseline to 4 weeks indicated that the patients were responsive to the anti-inlammatory efects of IM CS (Table  2 ). This response is also relected in 5 out of 8 patients experiencing clinically meaningful improvements in DAS28 (reduction >1.2) and CRP (reduction >10 mg/L) in the 4 weeks following CS injection (Table 2 ). Measures at 6-9 months indicated continued maintenance of control of disease activity and inlammation (data not shown), which was consistent with no reports of lares during this period.
Mean body composition changes over the study duration are shown in Table 3 . Four weeks following IM CS injection, an average of 0.93 kg ALM (i.e., MM) was lost, whereas mean total LM was reduced by 1.10 kg. All eight patients lost ALM in the month following IM CS injection, with seven losing >0.50 kg ( Table 2) . Mean proportional ALM (ALM/BM %, i.e., relative MM) was signiicantly reduced at 4 weeks post-injection. Although all mean measures of adiposity increased over this period, i.e., total FM (+0.70 kg), trunk FM (+0.53 kg), % body fat (+0.89%), and trunk FM % (+1.01%), none of these changes were statistically signiicant. Although there were no signiicant changes in any of the body composition measures between the follow-up assessments at 4 weeks and 6-9 months (p values=0.32-0.54), during which time control of inlammation and disease activity was maintained, LM measures tended to decline further, whereas FM measures regressed back to baseline levels (Table  3 ). Thus, 6-9 months after IM CS injection, the depletion in ALM observed at 4 weeks had not spontaneously reversed, and patients remained signiicantly muscle reduced relative to their baseline levels.
No changes in BMD or BMC were detected at 4 weeks or 6-9 months (data not shown; p values=0.620 or 0.664, respectively).
Discussion
To our knowledge, the present study is the irst to objectively investigate the consequences of a single, high-dose administration of CS on body composition. Although only preliminary, results from eight patients, taken with a similar observation from our case study, suggest that a single, high-dose IM CS injection used to treat active RA disease results in signiicant loss of ALM -a surrogate measure of skeletal MM (10) . As this reduction in MM is likely to have adverse efects on physical function, these indings raise important concerns about the routine use of this treatment for patients with RA with active disease.
Patients presenting with uncontrolled RA are often treated by IM CS injection. Indeed, such injections are recommended by national guidelines for the management of active RA (e.g., ACR, EULAR, BSR, and NICE) because of their eicacy in rapidly attenuating inlammation and pain (4) (5) (6) (7) (8) . Consistent with these recommendations and its regularly observed clinical beneit, the CS injections administered in the present study ameliorated disease activity and inlammation, with mean DAS28 and CRP at 4 weeks being reduced, relative to baseline, by 35% and 64%, respectively.
However, despite rapidly restoring control of inlammation and disease activity, there were mean losses of 0.93 kg and 1.46 kg in ALM (i.e., skeletal muscle), respectively, in the 4 weeks and 6-9 months following IM CS injection. This apparent iatrogenic loss of ALM accounts for approximately 37% of the discrepancy in proportional MM (i.e., ALM/BM %) between patients with RA and healthy age-and sexmatched individuals we have previously reported (3). Additionally, reduced MM, including the magnitude of MM loss observed in the present study (~7% of total MM), is acknowledged as a major contributor to the decreased strength and impaired physical function char- (1-3) . Further, loss of MM (and therefore loss of "expendable" protein) impairs the immune system's ability to adequately respond to infection and trauma (2) . It is important to note that despite sustained low disease activity, the muscle lost at 4 weeks was not spontaneously restored by the 6-9 months post-injection follow-up assessment. This inding is not unexpected, as without some form of anabolic stimuli the body does not spontaneously recover lost MM; and in speciic regard to patients with RA, this remains the case even when disease remission is achieved (3). This further emphasizes the importance for adjunct interventions designed to increase MM in RA. Of the potential anabolic interventions trialed, progressive resistance training is clearly the most beneicial intervention for improving both MM and physical functioning in patients with RA (12) .
With regard to the muscle loss we observed, an obvious question is whether this was a consequence of the inlammation associated with the disease lare. In response to this, we consider that systemic inlammation was unlikely to be a major contributor to the ALM loss seen in the present study because of i) the rapidity of the anti-inlammatory efects of high-dose CS, ii) the meaningful muscle loss (>0.5 kg ALM) observed 4 weeks following IM CS injection experienced by subjects (#2,4; Table 2 ) who did not have systemic inlammation according to blood CRP level at baseline, and iii) the lack of association (determined by linear regression) between ALM loss and either DAS28 or CRP at baseline (R 2 =0.009, p=0.822 or R 2 =0.063, p=0.549, respectively). Additionally, our indings of reduced MM following IM CS injection are consistent with the established efect on skeletal muscle of chronic high-dose CS treatment. While the exact mechanism underlying glucocorticoid-induced reduction in MM is unclear, augmented muscle protein breakdown via stimulation of the catabolic ubiquitin-proteasome system brought about by increased expression of atrogenes (genes, such as FOXO, Atrogin-1, and MuRF-1, involved in muscle atrophy) and attenuated muscle protein synthesis via inhibition of anabolic pathways (e.g., mTOR/ S6 kinase 1, PI3K/Akt, and insulin-like growth factor-I) have been observed (for a review see) (13) .
Given that IM CS injection is often administered to patients following diagnosis of RA and again when patients with established RA experience disease lares, it is not unusual for patients with RA to receive this form of treatment several times during the course of their disease (three occasions (range: 2-4) on average for the patients in the current study). Thus, this recommended treatment could be a signiicant contributor to RC and, in particular, the deiciency in MM observed in patients with RA.
Chronic CS use has also been implicated in the redistribution of fat to the truncal area (14) . Although we saw no mean change in patients' total FM, we did observe a non-signiicant 3.5% increase in trunk FM % at 4 weeks following acute administration of high-dose CS. As such, this is another aspect of body composition that warrants attention in a future large study evaluating the efects of one-of high-dose CS treatment. A shift in adiposity, if conirmed, would be worrying as trunk obesity, a feature of RA body composition, exacerbates cardiovascular disease risk (2, 3, 15) . However, it should be noted that, in contrast to the changes in LM measures observed at 4 weeks, the apparent changes observed in FM measures at 4 weeks had all been resolved by 6-9 months. Although chronic and acute IM CS uses are known to increase osteoporosis risk, we saw no changes in bone measures (BMD or BMC) at either timepoint (14, 16).
We acknowledge several limitations of our pilot study. First, the low n of our sample, and the inclusion of only patients with established RA who were experiencing a disease lare. These make it diicult to generalize the efect of IM CS injection we observed in all patients with RA, notably patients recently diagnosed with RA. Accordingly, to conirm the generality of these body composition effects of IM CS treatment for active RA, we have recently commenced a large, clinic-based study (n~100) which will mostly include treatment-naïve patients recently diagnosed with RA. However, in defense of the results from our pilot study, we feel that the very consistent pattern of muscle loss ( Table 2 , plus our case study) justiies concerns that IM CS injection may cause clinically meaningful muscle loss in patients with RA (10) . The lack of random and controlled treatment assignment may also be considered a weakness of our study design. However, this was unavoidable in a pragmatic, observational study of routine clinical practice. Additionally, denying treatment to patients with highly active RA would be unethical.
The results from this pilot study indicate that a single IM injection of high-dose CS, a recommended and standard treatment for uncontrolled disease activity in RA, causes substantial and clinically relevant loss of MM. Since shortterm, high-dose treatment with CS, including administration by IM injection, is undoubtedly the most cost-efective treatment currently available to combat high levels of inlammation in RA, we are not suggesting that this treatment is discontinued, as unresolved inlammation will also result in muscle loss (1) . However, we are advocating that ways of attenuating this apparent iatrogenic efect of IM CS injection should be investigated, as should potential alternative treatments for rapidly resolving the inlammation and pain of uncontrolled RA.
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